-
Viesearch·
-
@emedeventseditor·
Glecaprevir and Pibrentasvir for HCV in Kidney Disease
A 12-week treatment of glecaprevir and pibrentasvir in stage 4 or 5 chronic kidney disease patients with hepatitis C (HCV) resulted in a high response rate.
v6.7. We're a human-curated search engine and would love your feedback.
A 12-week treatment of glecaprevir and pibrentasvir in stage 4 or 5 chronic kidney disease patients with hepatitis C (HCV) resulted in a high response rate.